Celldex Therapeutics CLDX Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Celldex Therapeutics (CLDX) reported accretion (amortization) of discounts and premiums, investments of $630K in Q1 2026.
- How has Celldex Therapeutics's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Celldex Therapeutics's accretion (amortization) of discounts and premiums, investments decreased by 72.2% year-over-year, from $2.27M to $630K.
- What is the long-term trend for Celldex Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Over 3 years (2021 to 2025), Celldex Therapeutics's accretion (amortization) of discounts and premiums, investments has grown at a 19.8% compound annual growth rate (CAGR), from $3.41M to $5.86M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This metric represents the non-cash adjustments to the carrying value of investment securities resulting from the amortization of premiums or the accretion of discounts. It reflects the systematic recognition of interest income over the life of debt instruments held by the company. Investors use this to reconcile net income with actual cash flows generated from investment portfolios.